65,437 trials
Renal Failure · End Stage Renal Disease · Vascular Access
Primary: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV — 0 participants
Healthy
Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001
Neutropenia · Breast Cancer
Primary: Evaluate the Safety of F-627 for Injection in the Treatment of Female Postoperative Patients With Breast Cancer Who Require Adjuvant Chemotherapy. — 6; 6; 6; 6…
Female Stress Incontinence
Primary: Treatment Success — 8; 9 Participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Percentage of Participants
Advanced High-grade Ovarian Cancer · Triple Negative Breast Cancer
Primary: Phase 1: Number of Participants With Treatment- Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE) — 4; 4; 7; 0 Number of participants
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence (IBTR) — 2.7 percentage of participants
Leukemia, Myeloid, Acute
Primary: Primary Efficacy — 7 Participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 124.15; 215.66 Nanomoles *…
Localized T1-T2 Prostate Cancer
Primary: Primary Effectiveness Endpoint — 15.1 mm
Healthy
Primary: Area Under the Concentration-time Curve of BI 1595043 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — NA; NA hour*nanomol/Liter
Emotional Distress · Burnout, Professional · Stress, Job
Primary: Intervention Completion — 28 percentage of participants
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 6.7; 50.0; 33.3; 0.0 Percentage of participants
Surgery · Mobility
Primary: Characterize Number of Participants Who Tolerate Continuous vs Interval 40m Walk. — 10; 10 Participants
Immune Thrombocytopenia (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 0; 25 percentage of participants